Form 8-K - Current report:
SEC Accession No. 0001104659-22-049970
Filing Date
2022-04-26
Accepted
2022-04-26 07:24:43
Documents
14
Period of Report
2022-04-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2213489d1_8k.htm   iXBRL 8-K 34187
2 EXHIBIT 10.1 tm2213489d1_ex10-1.htm EX-10.1 24733
3 EXHIBIT 99.1 tm2213489d1_ex99-1.htm EX-99.1 13935
  Complete submission text file 0001104659-22-049970.txt   260493

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20220421.xsd EX-101.SCH 3036
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20220421_lab.xml EX-101.LAB 34476
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20220421_pre.xml EX-101.PRE 22597
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2213489d1_8k_htm.xml XML 3630
Mailing Address 3200 SOUTHWEST FREEWAY SUITE 2500 HOUSTON TX 77027
Business Address 3200 SOUTHWEST FREEWAY SUITE 2500 HOUSTON TX 77027 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 22851754
SIC: 2834 Pharmaceutical Preparations